Balanced news tone
News Sentiment
SRPT sentiment intelligence
SAREPTA THERAPEUTICS INC news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
47
Balanced news tone
32 relevant articles
News tone and price action are not far from neutral.
86/100 classification confidence.
directly relevant articles
high-authority source matches
+0.0% over one week, +4.6% over four weeks, trend inactive, and below fair value.
Sarepta Therapeutics Stock Short Interest Rises to 32.62%
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Primary event
Market update
86/100 classification
One-week reaction
0.0%
Price digesting
Trend fit
Trend inactive
4.6% over four weeks
Fair value
-59.2%
Below fair value
Value support
Sentiment Mix
Positive, neutral, negative
Positive
5
Neutral
21
Negative
6
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
Quiver Quantitative
Direct company coverage
Sarepta Therapeutics Stock Short Interest Rises to 32.62%
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 21 Jul 2026 13:28
- Source
- Quiver Quantitative
simplywall.st
Direct company coverage
Has Sarepta Therapeutics (SRPT) Fallen Below Fair Value After FDA Progress?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 19 Jul 2026 02:26
- Source
- simplywall.st
Market source
Direct company coverage
The Bull Case For Sarepta Therapeutics (SRPT) Could Change Following FDA sNDA Acceptance On DMD Therapies
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 14 Jul 2026 00:22
- Source
- Market source
DirectorsTalk Interviews
Direct company coverage
Sarepta Therapeutics (SRPT) Stock Analysis: Evaluating a 16.53% Potential Upside Amidst a Volatile Biotech Landscape
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 13 Jul 2026 09:22
- Source
- DirectorsTalk Interviews
Market source
Direct company coverage
Following FDA sNDA Acceptance Is Sarepta Therapeutics (SRPT) Still Undervalued?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 Jul 2026 07:00
- Source
- Market source
Investing.com
Direct company coverage
Wolfe Research upgrades Sarepta Therapeutics stock rating on pipeline outlook
- Tone
- Neutral 50/100
- Event
- Guidance
- Published
- 08 Jul 2026 07:00
- Source
- Investing.com
Investing.com
Direct company coverage
Sarepta Therapeutics options trading jumps to 5,295 contracts
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 Jun 2026 07:00
- Source
- Investing.com
Investing.com South Africa
Direct company coverage
Sarepta Therapeutics options trading jumps to 5,295 contracts By Investing.com
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 Jun 2026 07:00
- Source
- Investing.com South Africa
DirectorsTalk Interviews
Direct company coverage
Sarepta Therapeutics, Inc. (SRPT) Stock Analysis: Exploring a Potential 43.7% Upside in the Biotech Sector
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 15 Jun 2026 07:00
- Source
- DirectorsTalk Interviews
Market source
Direct company coverage
Why Is Sarepta Therapeutics (SRPT) Down 19.9% Since Last Earnings Report?
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 05 Jun 2026 07:00
- Source
- Market source
Market source
Direct company coverage
In Solid Cash Position, Sarepta Therapeutics Inc (SRPT) Outlines 2026 Priorities
- Tone
- Neutral 50/100
- Event
- Balance sheet
- Published
- 27 May 2026 07:00
- Source
- Market source
Market source
Direct company coverage
Assessing Sarepta Therapeutics (SRPT) Valuation After Recent Share Price Weakness
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 25 May 2026 07:00
- Source
- Market source
Market source
Direct company coverage
Why Elevidys Matters For Sarepta Therapeutics Inc (SRPT) Stock
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 20 May 2026 07:00
- Source
- Market source
Investing.com
Direct company coverage
Sarepta Therapeutics shares drop 10% on lower Elevidys revenue
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 07 May 2026 07:00
- Source
- Investing.com
geneonline.com
Direct company coverage
Sarepta Stock Falls as Investors Eye RNA Drugs, Despite Elevidys Gene Therapy Sales Outperforming Forecasts
- Tone
- Negative 22/100
- Event
- Market update
- Published
- 07 May 2026 07:00
- Source
- geneonline.com
Market source
Direct company coverage
Sarepta Therapeutics (SRPT) Soars 35.0%: Is Further Upside Left in the Stock?
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 26 Mar 2026 07:00
- Source
- Market source
Market source
Direct company coverage
Assessing Sarepta Therapeutics (SRPT) Valuation After Early siRNA Trial Results Spark Share Price Rebound
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 26 Mar 2026 07:00
- Source
- Market source
Investing.com
Direct company coverage
Sarepta stock surges 14% on early siRNA trial data
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 25 Mar 2026 07:00
- Source
- Investing.com
Investing.com
Direct company coverage
Leerink reiterates Market Perform on Sarepta stock after siRNA data
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 25 Mar 2026 07:00
- Source
- Investing.com
Market source
Direct company coverage
Sarepta (SRPT) Skyrockets 35% on Morgan Stanley PT Hike, Stellar Trial Results
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Mar 2026 07:00
- Source
- Market source
Investing.com
Direct company coverage
JPMorgan maintains Neutral rating on Sarepta stock after positive 3-year data
- Tone
- Positive 66/100
- Event
- Analyst action
- Published
- 27 Jan 2026 08:00
- Source
- Investing.com
Investing.com
Direct company coverage
H.C. Wainwright reiterates Sell rating on Sarepta Therapeutics stock
- Tone
- Negative 34/100
- Event
- Analyst action
- Published
- 14 Jan 2026 08:00
- Source
- Investing.com
Bloomberg.com
Direct company coverage
Sarepta Falls After Gene Therapy Elevidys Misses Estimates
- Tone
- Negative 5/100
- Event
- Earnings
- Published
- 12 Jan 2026 08:00
- Source
- Bloomberg.com
Bloomberg.com
Direct company coverage
Sarepta’s Elevidys to Remain on Market With New FDA Warning
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 14 Nov 2025 08:00
- Source
- Bloomberg.com
Clinical Trials Arena
Direct company coverage
Intellia Therapeutics’ stock rocked by patient death in gene therapy trial
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 07 Nov 2025 08:00
- Source
- Clinical Trials Arena
Reuters
Direct company coverage
Sarepta shares rebound after shipments of gene therapy Elevidys resume in US
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 Jul 2025 07:00
- Source
- Reuters
Stocktwits
Direct company coverage
Why Did Sarepta Stock Jump 20% On Tuesday? Here’s What JPMorgan, Bernstein, Barclays Said About Elevidys
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 Jul 2025 07:00
- Source
- Stocktwits
Bloomberg.com
Direct company coverage
Sarepta’s Duchenne Therapy Sparked Fears Even Before FDA’s Order
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 22 Jul 2025 07:00
- Source
- Bloomberg.com
Bloomberg.com
Direct company coverage
Sarepta Worth $0 Amid ‘Unwinnable’ FDA Fight, HC Wainwright Says
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 21 Jul 2025 07:00
- Source
- Bloomberg.com
Barron's
Direct company coverage
These Stocks Moved the Most Today: Sarepta, Verizon, Cleveland-Cliffs, Block, Tesla, DJT, Bruker, and More
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 21 Jul 2025 07:00
- Source
- Barron's